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Abstract 29 
 30 
Aims. Fabry disease (FD) is a rare X-linked lysosomal storage disease with a deficiency of α-31 
galactosidase A leading to progressive sphingolipid accumulation in different organs, among 32 
them heart and kidney. We evaluated the impact of cardio-renal syndrome (CRS) on the 33 
incidence of major cardiovascular complications and death in a prospective FD cohort. 34 
Methods and results. A total of 104 genetically proven FD patients were annually followed 35 
at the University Hospitals Zurich and Bern. The main outcome was a composite of incident 36 
renal replacement therapy (RRT), hospitalisation due to decompensated Heart Failure, new 37 
onset atrial fibrillation, pacemaker/ICD implantation, stroke/TIA and death. Estimated 38 
glomerular filtration rate (eGFR) and left ventricular myocardial mass index (LVMMI) where 39 
explored as the primary exposure variables. During the median follow-up of 103 [59-155] 40 
months, events occurred in 27 patients. In a Cox regression analysis, both higher LVMMI and 41 
lower eGFR were independently associated with a greater risk of developing adverse events 42 
after adjustment for multiple confounders (HR 1.67 [1.04-2.73], P=0.03 per SD increase in 43 
LVMMI, HR 0.45 [0.25-0.83], P=0.01 per SD decrease in eGFR). In patients with CRS, the 44 
risk to develop events was significantly increased if adjusted for demographics and RRT (HR 45 
4.46 [1.07-18.62], P=0.04), approaching significance if additionally adjusted for hypertension 46 
(HR 4.05 [0.95-17.29], P=0.06). In Kaplan-Meier-Analysis, the poorest event-free survival 47 
was observed among patients with CRS. 48 
Conclusions. CRS was associated with a high risk to develop cardiovascular complications 49 
and death, emphasizing the importance of its prevention and early recognition. A focus on 50 
cardio-reno-protective therapies is crucial. 51 
 52 
Keywords. Fabry disease, cardio-renal syndrome, risk factors  53 
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Introduction 54 
Fabry disease (FD) is an X-linked lysosomal storage disorder in which mutations of the GLA 55 
gene cause a decreased or absent activity of the enzyme alpha-galactosidase A (α-Gal A) and 56 
subsequent progressive intracellular accumulation of globotriaosylceramide (Gb3) and other 57 
sphingolipids in various tissues1,2. The initial classic signs and symptoms include 58 
acroparaesthesias, angiokeratoma, abdominal pain, hypohidrosis, corneal dystrophy and 59 
typically appear in childhood. With advancing age, vital organ dysfunction increasingly 60 
occurs resulting in cardiovascular disease, renal failure and premature strokes, on average 61 
more severely in males3. Combined renal and cardiac dysfunction is common in FD and 62 
associated with an increased mortality and morbidity risk4,5. 63 
Cardio-renal syndrome (CRS) is an increasingly recognized clinical entity which 64 
refers to the reciprocal association between cardiac and renal dysfunction, whereby injury to 65 
one organ directly promotes deterioration of the other6. This complex bilateral organ crosstalk 66 
can result from a variety of conditions where the primary failing organ may be the heart, the 67 
kidney or both. The latter is defined as CRS Type 5 and occurs secondarily to an underlying 68 
systemic process. FD is a typical example of the CRS Type 5, as described very recently7. 69 
CRS has been related to a particularly high morbidity and mortality in several settings6,8,9, 70 
however, little is known about its impact on adverse long-term outcomes in FD patients. 71 
In patients with FD, the indexed left ventricular myocardial mass (LVMMI) has 72 
repeatedly been shown to be a reliable parameter reflecting the onset and progression of Fabry 73 
disease-related cardiomyopathy10,11. The estimated glomerular filtration rate (eGFR) has been 74 
used to quantify the renal involvement and shown to be a major risk factor for cardiovascular 75 
complications in FD5. The aim of this study was to assess the impact of CRS, reflected by 76 
LVMMI and eGFR, on clinical outcomes in a large prospective multicentre cohort of 77 
genetically confirmed FD patients and a long-term follow-up. The recognition of CRS should 78 
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lead to specific prevention strategies and therapeutic approaches in order to at least attenuate 79 
the organ failure in those patients.  80 
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Methods 81 
This is a retrospective analysis of a prospective, multi-centre cohort in Switzerland. The study 82 
was conducted in accordance with the principles of the Helsinki Declaration. The patients 83 
who could be contacted gave written informed consent. The authors have read and approved 84 
the manuscript. 85 
 86 
Study population and treatment 87 
The prospective FD cohort consisted of 104 patients, who were genetically tested (for further 88 
information see the Supplementary Table online). The cohort was established in 2001 when 89 
enzyme replacement therapy (ERT) was newly developed and offered to all FD patients. 90 
Consecutive FD patients were registered and received routine annual multidisciplinary 91 
examinations at two tertiary care hospitals – University Hospitals Zürich (93 patients) and 92 
Bern (11 patients). Here, we report on the clinical course and adverse outcomes of 64 females 93 
and 40 males. 94 
The baseline clinical evaluation was performed at the time the patients were included 95 
in the cohort. For the present analysis, the clinical data and information on hospitalisation 96 
were extracted from medical records. 97 
FD patients in Switzerland are personally followed-up and examined at the Fabry 98 
Centres, the adverse events were evaluated during annual examinations. All patients had a 99 
comprehensive workup, including medical history, cardiac evaluation with echocardiography, 100 
renal, and neurological evaluations. A 24- or 48 hours ECG was performed annually and 101 
additionally if patients complained of palpitations or chest pain. Hospitalisation was defined 102 
as a hospital stay for at least 24 hours. Standard transthoracic 2D-echocardiography was 103 
routinely performed in all patients. 104 
For the evaluation of diastolic dysfunction, the left atrial volume index (LAVI), the 105 
mitral inflow (E/A ratio) and the mitral annular movement with tissue Doppler (e’ septal and 106 
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lateral as well as an average of E/e’ ratio) was measured according to the current practice 107 
guidelines 12,13. These measurements were performed using continuous recordings of mitral 108 
inflow, analysing the pulsed-wave during 10 seconds: the peak E-wave velocity (cm/sec) in 109 
early diastole, the A-wave (cm/sec) in late diastole at the leading edge of the spectral 110 
waveform and the pulsed wave tissue Doppler e’ velocity (cm/sec) in early diastole. These 111 
measurements were available in the Zurich subgroup (N=82) of patients. Diastolic 112 
dysfunction has been graded according to the recent algorithm from the ASE/EACVI 113 
recommendations for the evaluation of the left ventricular diastolic function13 by reviewing 114 
and repeating all measurements of the archived echocardiographic studies.  115 
Enzyme replacement therapy was initiated according to the written local guidelines 116 
and prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant 𝛼-117 
agalsidase (Replagal) or 1 mg/kg body weight 𝛽-agalsidase (Fabrazyme) and given 118 
intravenously every 14 days. According to the guidelines, ERT was indicated in all males. In 119 
females, ERT was indicated if they had proteinuria of more than 300 mg per day, Fabry-120 
typical kidney biopsy findings, signs of Fabry cardiomyopathy such as left ventricular 121 
hypertrophy or arrhythmia, stroke or transient ischemic attack (TIA), acroparesthesias despite 122 
conventional analgesic therapy, and/or gastrointestinal symptoms. 123 
 124 
Endpoint definition and evaluation 125 
As a primary endpoint, we defined the composite of requiring renal replacement therapy 126 
(RRT) (kidney transplantation or chronic dialysis), newly diagnosed atrial fibrillation (AF) of 127 
any type (paroxysmal/persistent), pacemaker and/or ICD implantation, hospitalisation due to 128 
decompensated heart hailure (HF), cerebrovascular events (stroke or TIA), and death, 129 
whichever occurred first. The follow-up was censored at the date of the first event to calculate 130 
hazard ratios. The follow-up time for patients without events was censored at the 1st of July 131 
2015. If the patients died outside of the Fabry Centre, the date of death was evaluated by 132 
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asking the responsible General Practitioner, the family or the nurse administering ERT in the 133 
home care setting. 134 
 135 
Primary exposure variables: cardiac and renal involvement 136 
LVMMI at baseline was used as the primary exposure variable to express cardiac 137 
involvement. For this, standard transthoracic 2D echocardiography was routinely performed 138 
in all patients. Left ventricular end-diastolic dimension and end-diastolic thickness of the 139 
posterior wall and the septum were measured using standard M-mode echocardiographic 140 
methods in parasternal long-axis images. LVMMI was calculated using the Devereux 141 
formula14. 142 
Estimated glomerular filtration rate (eGFR) at baseline was used as the primary 143 
exposure variable to express renal involvement. The eGFR was derived from serum creatinine 144 
and age using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 15. The 145 
CKD-EPI equation is known to have a similarly good statistical performance as previously 146 
used equations when the estimated GFR is below 60 ml/min/1.73m2, but with better 147 
performance in those with higher eGFR levels16. 148 
 149 
Statistical analysis 150 
We used descriptive statistics for the baseline characteristics and laboratory parameters. 151 
Categorical variables were expressed as proportions, continuous variables as means with 152 
standard deviations and medians with interquartile ranges (IQR). Normal distribution was 153 
assessed by the Kolmogorov-Smirnov-Test. 154 
The cut-off values for LVMMI and eGFR were calculated by maximizing the product 155 
of sensitivity and specificity by using receiver operating curve characteristics (ROCs). 156 
Kaplan-Meier analysis was performed for event-free survival and log-rank values to assess 157 
statistical significance. 158 
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Cox regression analysis was used to examine the risk of adverse events associated 159 
with baseline LVMMI and eGFR on a continuous scale and for cardiac, renal and cardio-renal 160 
involvement as categorical variables. For the categorization, cardiac involvement was defined 161 
as LVMMI above the best calculated cut-off value of 107 (g/m2), we used this value for both 162 
genders because males have a higher LVMMI and a higher risk to develop adverse outcomes 163 
due to the hemizygosity; renal involvement was defined as eGFR below the best calculated 164 
cut-off value of 90 ml/min/1.73m2; CRS was defined as LVMMI > 107 (g/m2) and eGFR < 90 165 
ml/min/1.73m2. 166 
Multivariable models were applied to adjust for potential confounders using prior 167 
knowledge of variables that have been associated with risk in FD patients in previous studies. 168 
We hierarchically adjusted for demographics (age, gender) in model 1, RRT (kidney 169 
transplant or dialysis at baseline) in model 2 and presence of arterial hypertension (systolic 170 
RR > 140 or diastolic RR > 90 mmHg or intake of antihypertensive drugs) in model 3. These 171 
models were used for all multivariable Cox regression analyses. 172 
To evaluate the effect of ERT on the primary endpoint, Cox regression analysis was 173 
used, where ERT was expressed as a categorical covariate. In a multivariate Cox regression 174 
analysis, an adjustment for age and gender and for cardio-renal involvement was applied to 175 
evaluate if the ERT effect remained independent. 176 
The statistical analyses were performed using the SPSS/PC (version 22.0; SPSS Inc., 177 
Chicago, IL, USA) software package. All statistical tests were two-sided, and P values <0.05 178 
were considered significant. 179 
180 
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Results 181 
The baseline characteristics of all patients according to gender and to the presence of CRS are 182 
shown in Table 1. In total, 104 patients (40 males and 64 females) with a mean age of 45 ± 16 183 
years were included into the analysis. A baseline echocardiography was available in 91, 184 
results on diastolic dysfunction in 82 patients. The left ventricular ejection fraction (LVEF) 185 
was normal in all patients. The patients with cardio-renal involvement at baseline were older, 186 
had more frequently a Classic disease phenotype, arterial hypertension, echocardiographic 187 
signs of diastolic dysfunction, had higher serum NT-proBNP levels and elevated urine 188 
protein/creatinine ratios. 189 
Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin receptor blocker 190 
(ARB) were used in 17 (16%) of the 104 patients at baseline. During the follow-up time, 191 
ACE-i or ARB were started in a further 17 patients. 192 
The NYHA classes at baseline are summarized in Table 1. At the end of the follow-up 193 
time, NYHA I/II was present in 23 (22%) patients: 7 (18%) males, 16 (25%) females and 10 194 
(23%) in patients with CRS at baseline; NYHA III/IV was present in 9 (8.6%) patients: 5 195 
(13%) males, 4 (6.3%) females and 5 (12%) patients with CRS at baseline. NYHA class 196 
increased in 24 (23%) patients: 11 (28%) males, 13 (20%) females and 9 (21%) CRS patients. 197 
48 patients were treated with α-agalsidase and nine with β-agalsidase throughout the 198 
follow-up time. Eight patients were switched from β-agalsidase to α-agalsidase (seven due to 199 
shortage of β-agalsidase, one at the discretion of the treating physician), one from α-200 
agalsidase to β-agalsidase (due to patient’s priority) an one from β-agalsidase to α-agalsidase 201 
(due to shortage) and back to β-agalsidase (due to patient’s priority).  202 
 203 
Events 204 
During the median follow-up time of 105 [45-139] months, the first event occurred in 27 205 
(26%) of the patient population: in 11 patients, the first event was stroke or TIA, in 2 kidney 206 
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transplantation, in 4 chronic dialysis, in 2 hospitalisation due to decompensated HF, in 8 207 
death. 15 (56%) of the 27 patients who developed an event during the follow-up time had 208 
cardio-renal involvement at baseline. A pacemaker implantation or AF did not occur as a first 209 
event. 210 
Overall, 57 events occurred: 4 patients had a new kidney transplantation, of whom 3 211 
(75%) had cardio-renal involvement at baseline; 4 began chronic dialysis, of whom 3 (75%) 212 
had cardio-renal involvement at baseline; 2 patients were hospitalised due to decompensated 213 
HF, both (100%) with cardio-renal involvement at baseline; 11 had at least one stroke or TIA, 214 
8 (73%) of whom had cardio-renal involvement at baseline; 7 had new-onset AF, of whom 6 215 
(86%) had cardio-renal involvement at baseline; 6 underwent pacemaker and/or ICD 216 
implantation (with one appropriate shock secondary to sustained ventricular tachycardia in 217 
one patient during the entire follow-up period), all of whom had cardio-renal involvement at 218 
baseline. Of these 6 patients, 3 received a pacemaker due to symptomatic second- or third-219 
degree atrioventricular block and one due to sinus dysfunction; 3 had an ICD implanted due 220 
to recurrent sustained and hemodynamically not tolerated ventricular tachycardia. 11 patients 221 
died: 2 due to cardiac arrhythmia, 2 malignancy, 1 infection, 1 suicide, 5 unknown; 6 (55%) 222 
of the deceased had cardio-renal involvement at baseline. The two male patients (59 and 47 223 
years old) who died from cardiac arrhythmia, (one ventricular tachycardia and one asystole 224 
with pulseless electrical activity) suffered from cardiomyopathy, had kidney transplantation 225 
and a moderate infection.  226 
The prognostic accuracy of baseline LVMMI and eGFR to predict major adverse 227 
clinical events using ROC curves was moderate to high as shown in the supplementary 228 
material (figure 1). We calculated an area under the curve of 0.81 for LVMMI and 0.86 for 229 
GFR. The best calculated cut-off for the events development was 107 g/m2 for LVMMI and 230 
90 ml/min/1.73m2 for eGFR. 231 
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When examining continuous variables using Cox regression analysis, both higher 232 
LVMMI (Table 2A) and lower eGFR (Table 2B) at baseline were associated with a greater 233 
risk of developing an adverse clinical event in the crude model, after adjustment for possible 234 
confounders in model 1, model 2 and in the fully adjusted model 3. Of note, LVMMI and 235 
eGFR were associated with adverse events independently from each other if included into the 236 
same fully adjusted model (Table 2B). 237 
Protein/creatinine ratio in a random urine sample and cholesterol levels were not 238 
associated with the adverse events in the crude model. These data are not shown. Smoking 239 
was associated with adverse events in the crude Cox regression analysis (HR 2.28 [1.03-5.03], 240 
P=0.04) but lost its independent effect on event occurrence after adjustment for male gender 241 
(HR 2.05 [0.91-4.63], P=0.09). 242 
When examining categorical variables in a Cox regression analysis where (i) cardiac 243 
involvement is defined as LVMMI above the best calculated cut-off (>107 g/m2), (ii) renal 244 
involvement as eGFR below the best calculated cut-off (<90 ml/min/1.73m2) and (iii) CRS as 245 
both simultaneously, the risk to develop events was higher in patients with CRS as compared 246 
to all patients with cardiac and to all patients with renal involvement (Table 3) in a crude 247 
model. The Cox regression model for CRS remained significant after adjusting for possible 248 
confounders in model 1 and model 2, and approached significance in the fully adjusted model. 249 
The cumulative dose of ERT did not influence the occurrence of clinical events for α-250 
agalsidase, β-agalsidase and the sum of both in patients with cardiac (HR 0.88 [0.68-1.15], 251 
P=0.36 for α-agalsidase; HR 1.04 [0.97-1.11], P=0.24 for β-agalsidase; HR 1.04 [0.96-1.12], 252 
P=0.36 for sum), renal (HR 0.89 [0.73-1.08], P=0.24 for α-agalsidase; HR 1.06 [1.00-1.13], 253 
P=0.07 for β-agalsidase, HR 1.04 [0.97-1.12], P=0.23 for sum) and cardio-renal (HR 0.85 254 
[0.64-1.12], P=0.24 for α-agalsidase; HR 1.05 [0.98-1.12], P=0.20 for β-agalsidase; HR 1.04 255 
[0.87-1.12], P=0.35 for sum) involvement (all per 1 g increase and in fully adjusted model). 256 
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If defining only RRT, hospitalisation due to decompensated HF, cerebrovascular 257 
events (stroke or TIA), and death as the endpoint for the Cox regression model, excluding AF 258 
as an event of a less clinical severity, higher LVMMI and lower eGFR at baseline remained 259 
associated with a greater risk of developing an adverse clinical event in the crude model (HR 260 
2.21 [1.43-3.42], P<0.001 for LVMMI, HR 0.41 [0.27-0.62], P< 0.001 for eGFR), and 261 
remained significant for the eGFR approaching the significance for LVMMI after adjustment 262 
for possible confounders in model 1, (HR 1.65 [0.91-2.97], P=0.10 for LVMMI, HR 0.41 263 
[0.24-0.71], P= 0.001 for eGFR) model 2, (HR 1.74 [0.94-3.20], P=0.08 for LVMMI, HR 264 
0.37 [0.20-0.70], P=0.002 for eGFR) and in the fully adjusted model 3 (HR 1.76 [0.98-3.18], 265 
P=0.06 for LVMMI, HR 0.39 [0.20-0.76], P=0.006 for eGFR) (all models per SD increase in 266 
LVMMI and SD decrease in eGFR). 267 
When examining the effects of ERT on event occurrence, patients on ERT were at 268 
higher risk in the crude model (HR 11.62 [1.57-86.05], P=0.02) and after adjustment for age 269 
and gender (HR 9.37 [1.21-72.47], P=0.03). However, this “negative” ERT effect was 270 
attenuated after adjustment for cardio-renal involvement at baseline (HR 6.09 [0.76-49.06], 271 
P=0.09). 272 
In the Kaplan-Meier-Analysis, the poorest event-free survival was observed among 273 
patients with baseline cardio-renal involvement (Figure 1, A-C). This effect outweighed the 274 
gender-related difference in outcome within the cohort (Figure 1, D). 275 
The associations remained unchanged if patients with the mutations c.376A>G / 276 
p.S126G and c.416A>G / p.N139S were excluded from the analysis, due to genetic variants 277 
of unknown significance. 278 
 279 
Diastolic dysfunction 280 
At baseline, 22 of 82 (27%) patients had a diastolic dysfunction. Of them, six (27%) showed 281 
an abnormal relaxation pattern - corresponding to diastolic dysfunction grade 1; twelve (55%) 282 
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pseudonormal filling dynamics - grade 2; three (14%) restrictive filling dynamics – grade 3; 283 
one (4.5%) was inconclusive.  284 
When analysing the parameters of diastolic dysfunction on a continuous scale, E/e` was a 285 
significant predictor for the occurrence of adverse clinical events in a crude (HR 1.90 [1.44-286 
2.50], P<0.001) model and remained an independent predictor in model 1 (HR 1.63 [1.3-287 
2.35], P=0.01), model 2 (HR 1.68 [1.15-2.46], P=0.007) and model 3 (HR 1.85 [1.23-2.78], 288 
P=0.003]) (per SD increase). In contrast, LAVI predicted event occurrence in the crude (HR 289 
1.85 [1.33-2.57], P<0.001) but not in the adjusted models (HR 1.23 [0.80-1.88], P=0.35 for 290 
model 1, HR 1.31 [0.81-2.12], P=0.27 model 2 and HR 1.49 [0.89-2.52], P=0.13 model 3, (all 291 
per SD increase). 292 
 293 
Hospitalisations 294 
All-cause hospitalisations. Overall, 28 of 104 patients were hospitalised during the follow-up 295 
period: 15 of 29 (52%) patients with and 13 (17%) of 75 without cardio-renal syndrome at 296 
baseline were ever hospitalised. 297 
From a total of 79 hospitalisations (15 due to cardiac event or cardiac-related 298 
procedure; 8 TIA or stroke, 10 related to RRT, 4 due to pain, 23 infection, 2 malignancy, 17 299 
other), 57 (72%) occurred in patients with and 22 (28%) without cardio-renal syndrome at 300 
baseline. 301 
 302 
Cardiac hospitalisations 303 
Overall, 9 of 104 patients were hospitalised due to a cardiac event or procedure. All of these 304 
patients had cardio-renal syndrome at baseline. In total, 15 cardiac hospitalisations occurred: 305 
8 due to pacemaker/ICD implantation and related complications, 2 acute coronary events, 2 306 
aortic valve replacements, 2 decompensated heart failure, 1 arrhythmic event.  307 
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Discussion 308 
In this prospective multicentre cohort of 104 Swiss Fabry patients, CRS was associated with a 309 
high risk of complications such as death, stroke/TIA, hospitalisation due to decompensated 310 
HF and requirement for renal replacement therapy. Cardiac and renal disease independently 311 
increased the risk for major clinical events. Interestingly, cardio-renal involvement was a 312 
more important independent risk factor than male gender, despite the fact that FD is an X-313 
linked inherited disorder. 314 
Concurrent cardiac and renal involvement may reflect an advanced Gb3 deposition in 315 
the vital organs. Indeed, studies have demonstrated that patients with advanced stages of FD 316 
tend to experience disease progression and benefit less from enzyme replacement therapy17,18. 317 
Moreover, cardio-renal involvement was often associated with the more severe classic FD 318 
phenotype; in contrast, single-organ manifestations seemed to correspond to the later-onset 319 
phenotype, which is known for a milder vascular risk profile19. Furthermore, renal disease 320 
itself has been shown to be a major risk factor for cardiovascular complications in FD 5. 321 
Similarly, left ventricular hypertrophy was a significant predictor for cardiovascular events in 322 
a large-scale registry-based long-term study20. 323 
Additional pathophysiological mechanisms beyond glycosphingolipid deposition have 324 
been proposed to enhance the cardio-renal problem in patients with Fabry disease. On the 325 
cellular level, the lysosomal dysfunction may trigger a damaging cascade of events such as 326 
cell apoptosis, energy depletion21, increased oxidative stress22, inflammation23 and finally 327 
cardiac24,25 and renal tissue fibrosis26,27. On the organ level, left ventricular hypertrophy, 328 
diastolic dysfunction and arrhythmia can lead to a reduced cardiac output and a consecutive 329 
arterial underfilling resulting in reduced renal perfusion as well as renal venous congestion. 330 
On the other hand, reduced glomerular filtration rate causes salt and water retention, azotemia 331 
and acid base imbalance, further increasing the cardiac preload and predisposing to left 332 
ventricular and diastolic dysfunction. These haemodynamic derangements likely result in an 333 
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activation of the renin-angiotensin-aldosterone-system and a release of vasoactive mediators 334 
responsible for systemic vasoconstriction. Along the same lines, arterial hypertension has 335 
repeatedly been shown as an important risk factor in Fabry disease progression20. 336 
As shown in this study, diastolic dysfunction plays an important prognostic role in FD. 337 
Diastolic dysfunction is known to be an early sign of cardiac involvement in FD occurring 338 
before LVH28. Our results are in line with a study by Boyd et al, in which left atrial 339 
enlargement and reduced atrial compliance in particular were shown as crucial early signs of 340 
Fabry cardiomyopathy28. This left atrial enlargement as a result of chronic left atrial pressure 341 
elevation may lead to renal venous congestion, initiating the vicious cycle of CRS. 342 
Cardiac and renal deterioration should consequently be prevented as far as possible in 343 
order to reduce morbidity and mortality. Within our cohort, patients on ERT were still at an 344 
increased risk of developing adverse clinical events, which continued to occur independently 345 
of the cumulative ERT dose, even after adjustment for possible confounders. The most likely 346 
reason for this observation is that ERT was indicated in patients with more severe phenotypes 347 
and was initiated relatively late. Importantly, we studied an “old” FD population where a 348 
large proportion of the patients had advanced disease, ERT having been initiated and offered 349 
to all FD patients from 2001. In this cohort, a high proportion of females (48%) was on ERT 350 
but could have been at lower risk of having major clinical events due to the heterozygosity. 351 
Therefore, in order to avoid bias by gender, adjustment for gender as a possible confounder 352 
has been introduced already in Model 1 and maintained in all multivariate models.  353 
Of note in this study, we adopted a definition of CRS leading to a focus on patients 354 
with relatively “advanced“ disease. Importantly, we studied an “older” adult FD population 355 
where a large proportion of the patients had advanced disease at baseline, because the cohort 356 
was established when ERT was initiated and offered to all FD patients in 2001. In the future, 357 
it is important to study the association of early disease involvement with clinical events 358 
because early ERT initiation benefits the clinical long-term outcome17,29. 359 
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Because Gb3 accumulation is known to occur at early stages of Fabry 360 
nephropathy30,31 and cardiomyopathy32, early initiation of enzyme replacement therapy prior 361 
to overt kidney and heart disease may lead to prevention of CRS. Studies suggest that 362 
maximal treatment effect can be achieved at early stages of heart and kidney involvement33,34. 363 
To slow disease progression, more intensive therapies such as increased ERT dose or 364 
additional pharmacological chaperone therapy could enhance the therapeutic outcomes35-37. 365 
Fabry patients with advanced cardio-renal disease might additionally benefit from general 366 
therapies used to control cardiac and renal disease by RAAS inhibition using angiotensin-367 
converting enzyme inhibitors or angiotensin blockers in the chronic and diuretic therapy in 368 
the acute setting. Patients with advanced disease should undergo a routine organ staging at 369 
regular intervals38 and be treated according to current guidelines39. 370 
We included five patients with mutations c.376A>G / p.S126G  and c.416A>G / 371 
p.N139S, reported in literature as genetic variants of unknown significance40-43. Three males, 372 
55, 45 and 23 year old, and one female, 53 year old, with the mutation c.376A>G / p.S126G, 373 
had no cardiac or renal involvement at baseline and at 4 years follow-up, which confirms a 374 
rather benign nature of this mutation. Similarly, the 43 year old female with the mutation 375 
c.416A>G / p.N139S had no cardiac or renal involvement at baseline and at 2 years follow-376 
up.  Importantly, the associations with the clinical outcomes remained unchanged if patients 377 
with these mutations were excluded from the analysis.” 378 
Several limitations merit consideration. Firstly, due to a relatively small cohort size, 379 
we had to define a composite outcome in order to increase the power of this study. Secondly, 380 
cardiac MRI was not available at cohort initiation. Thirdly, we cannot conclude from this 381 
study to what extent patients with cardio-renal involvement benefited from enzyme 382 
replacement therapy. 383 
The strengths of this study are its long observational period for hard clinical outcomes 384 
in a multicentre cohort in a single country, where patients are treated similarly and exposed to 385 
17 
 
similar environmental conditions, and its negligible loss to follow-up. The latter is due to 386 
Swiss regulation that the ERT prescription and patients` follow-up remains reserved for the 387 
Fabry Centres. 388 
In conclusion, cardio-renal involvement in Fabry disease is a potential marker of 389 
disease progression bearing an increased risk of mortality and cardiovascular events. 390 
Multidisciplinary care provided by cardiologists, nephrologists, general physicians and other 391 
specialists is important in treating the Type 5 cardio-renal syndrome seen in Fabry disease. 392 
 393 
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Figures 
 
Figure 1 
Time to first complication in Fabry patients presented in groups using the best calculated cut-offs for 
LVMMI and eGFR at baseline (A), eGFR at baseline (B), LVMMI at baseline (C) and according to gender 
(D). 
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Table 1 Baseline characteristics, and laboratory parameters and cumulative ERT dose 
 
 
All patients Males  Females  Patients with cardio-renal 
involvement1 
 
(n=104) (n= 40) (n=64) (n=29; Males n=14) 
Age (years) 45 ± 16 48 ± 14  44 ± 17 60 ± 10 
Phenotype      
Classic  n (%) 89 (86) 33 (83) 56 (88) 28 (97) 
Later-Onset n (%) 15 (14) 7 (17) 8 (12) 1 (3) 
BMI, (kg/m2) 22 (20-25) 22 (19-23) 22 (20-26) 23 (22-25) 
ERT n (%) 2 65 (63)  35 (88)  31 (48) 25 (86) 
   Cumulative dose α-agalsidase, g  3.0 (1.4-4.4) 3 3.4 (2.1-4.6) 2.2 (0.9-3.2) 3.4 (1.9-4.5) 
   Cumulative dose β-agalsidase, g 13.2 (5.1-19.3) 3 13.2 (6.5-21.8) 10.6 (4.2-16.9) 17.7 (10.2-20.6) 
Mainz Severity Score Index 15 ± 11 21 ± 11 11 ± 8 25 ± 10 
Systolic BP (mmHg) 120 (110-131) 124 (115-133) 120 (110-130) 129 (120-138) 
Diastolic BP (mmHg) 80 (70-82) 80 (75-85) 78 (70-80) 80 (73-90) 
Arterial hypertension n (%) 
 On ACE-i/ARB (%) 
27 (26) 
17 (16) 
15 (38) 
12 (30) 
12 (19) 
5 (8) 
16 (55) 
9 (31) 
Diabetes mellitus n (%) 1 (1) 0 1 (2) 0 
Cholesterol (mmol/l) 4.6 (4.1-5.6) 4.3 (3.9-5.4) 4.9 (4.2-5.7) 5.2 (4.3-6.1) 
Smoker n (%) 37 (36) 21 (53) 16 (25) 12 (41) 
NYHA I/II n (%) 
NYHA III/IV n (%) 
13 (13) 
5 (4.8) 
5 (13) 
1 (2.5) 
8 (13) 
4 (6.3) 
9 (21) 
3 (7) 
NT-proBNP, ng/l  435 ± 1222 683 ± 1938 305 ± 614 1083 ± 2131 
Creatinine (µmol/l) 75 (67-91) 93 (82-132) 71 (64-76) 94 (75-131) 
Protein/creatinine-ratio in urine (m g/mmol) 9 (6-24) 13 (7-39) 8 (4-17) 18 (9-42) 
Chronic dialysis 4 n (%) 7 (7)  7 (18) 0 3 (10) 
Renal transplantation n (%) 8 (8) 8 (20) 0 4 (14) 
LVMMI (g/m²) 89 (64-127) 109 (80-147) 75 (58-116) 147 (124-190) 
LAVI (ml/m2) 28 ± 11 30 ± 13 27 ± 10 39 ± 11 
E/e (cm/sec) 8 ± 6 8 ± 3 8 ± 7 12 ± 8 
Ejection Fraction, %  65 ± 7 65 ± 7 64 ± 6 66 ± 7 
Atrial fibrillation n (%) 1 (1) 1 (2.5) 0 (0) 0 (0) 
Pacemaker 1 (1) 0 (0) 1 (1.6) 0 (0) 
Abbreviations:  ACE-i =  angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index;  BP = blood pressure ERT 
= enzyme-replacement therapy; HR=Hazard Ratio;; LVMMI = left ventricular myocardial mass index, NYHA New York Heart Association functional class;  
TIA= transient ischemic attack. 
 
Data are given as mean ± standard deviation, median (interquartile range) or numbers (%).  
 
1 patients with concurrent cardiac (LVMMI>107 g/m2) and renal (eGFR<90 ml/min/1.73m2) involvement at baseline 
2 four males were untreated due to mild phenotype, one due to compliance issue  
3 only patients on ERT included in this analysis 
4 at baseline or before kidney transplantation 
2 
 
Table 2 A. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline 
LVMMI.  
 
 
Parameter Crude   Model 
1 
  Model 
2 
  Model 
3 
  
 HR CI P HR CI P HR CI P HR CI P 
LVMMI (g/m2)** 2.14 1.52-
3.01 
<0.001 1.65 1.06-
2.58 
0.03 1.67 1.04-2.73 0.03 1.67 1.04-
2.73 
0.03 
Age    1.03 1.00-
1.07 
0.045 1.03 1.00-1.07 0.06 1.02 0.98-
1.06 
0.26 
Gender    1.56 0.63-
3.87 
0.34 1.68 0.66-4.32 0.28 1.55 0.60-
3.97 
0.37 
Kidney transplant       0.47 0.07-3.18 0.44 0.42 0.07-
2.66 
0.36 
Dialysis       2.36 0.41-
13.68 
0.34 2.05 0.11-
3.21 
0.40 
Hypertension           1.92 0.71-
5.21 
0.20 
eGFR          0.32 0.16-
0.61 
0.001 
Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR= estimated glomerular filtration rate; HR=Hazard Ratio; CI=confidence 
interval 
Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 
3: additionally adjusted for presence of hypertension at baseline  
* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic 
dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, 
cerebrovascular events (stroke or TIA), death 
**per SD decrease 
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Table 2B. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline eGFR.  
 
Parameter Crude   Model 
1 
  Model 
2 
  Model 
3 
  
 HR CI P HR CI P HR CI P HR CI P 
eGFR** 0.42 0.28-
0.61 
<0.001 0.45 0.27-
0.74 
0.002 0.42 0.24-
0.74 
0.003 0.45 0.25-
0.83 
0.01 
Age    1.01 0.97-
1.04 
0.76 1.00 0.97-
1.04 
0.85 1.00 
 
0.97-
1.04 
0.98 
Gender    1.30 0.56-
3.02 
0.54 1.32 0.51-
3.38 
0.57 1.23 0.47-
3.21 
0.67 
Kidney 
transplant 
      0.97 0.21-
4.59 
0.97 1.06 0.23-
4.94 
0.94 
 
Dialysis       0.75 0.16-
3.68 
0.73 0.79 0.16-
3.78 
0.76 
Hypertension           1.52 
 
0.58-
3.99 
0.40 
Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR= estimated glomerular filtration rate; HR=Hazard Ratio; CI=confidence 
interval 
Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 
3: additionally adjusted for presence of hypertension at baseline  
* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic 
dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, 
cerebrovascular events (stroke or TIA), death 
**per SD decrease 
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Table 3. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline cardiac, 
renal and cardio-renal involvement.  
 
 Cardiac involvement 1 (N=38)  Renal involvement 2 (N=49)  Cardio-renal involvement 3 (N=29)  
 HR 95%CI P HR 95%CI P HR 95%CI P  
Crude 4.28 1.58-11.56 0.004 6.38 1.91-21.33 0.003 7.42 2.73-20.23 <0.001 
Model 1 1.79 
 
0.55-5.82 0.37 4.30 1.06-17.52 0.04 4.10 1.05-15.99 0.04 
Model 2 1.83 0.56-5.97 0.32 4.88 1.12-21.24 0.04 4.46 1.07-18.62 0.04 
Model 3 1.75 0.54-5.69 0.35 4.41 0.97-20.06 0.06 4.05 0.95-17.29 0.06 
1 all patients with cardiac (LVMMI>107 g/m2) involvement at baseline 
2 all patients with renal (eGFR<90 ml/min/1.73m2) involvement at baseline 
3 patients with concurrent cardiac (LVMMI>107 g/m2) and renal (eGFR<90 ml/min/1.73m2) involvement at baseline 
 
Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 
3: additionally adjusted for presence of hypertension at baseline 
 
* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic 
dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, 
cerebrovascular events (stroke or TIA), death 
 
Supplementary Table 1. Genotype and phenotype of the included Fabry patients  
 
 
Sex 
 
Age  GLA Mutation  /  Predicted Enzyme Protein Change Phenotype 
 male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
male 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
33 
35 
23 
44 
67 
51 
36 
47 
44 
49 
39 
55 
59 
61 
59 
39 
41 
60 
61 
29 
27 
59 
40 
56 
68 
34 
35 
73 
40 
44 
60 
50 
75 
63 
48 
26 
31 
29 
25 
36 
69 
48 
52 
44 
c.125T>C / p.M42T 
c.125T>C / p.M42T 
c.125T>C / p.M42T 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.613C>T / p.P205S 
c.744_745delTA / p.F248LfsX7 
c.744_745delTA / p.F248LfsX7 
c.827G>A / p.S276N 
c.899T>A / p.L300H 
c.899T>A / p.L300H 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1055_1057dupCTA / p.A352_M353insT 
c.1147_1149del / p.F383del 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT  / p.V390CfsX9  
IVS6-10G>A / Cons. Splice Site  
c.370-2A>G / Cons. Splice Site 
c.370-2A>G / Cons. Splice Site 
c.640-3C>G / Cons. Splice Site 
Whole Exon 2 / Null-allele 
Whole Exon 2 / Null-allele 
c.72G>A / p.W24X 
c.72G>A / p.W24X 
c.125T>C / p.M42T 
c.125T>C / p.M42T 
c.125T>C / p.M42T 
c.125T>C / p.M42T 
c.154T>C / p.C52R 
c.365delA / p.N122IfsX8 
c.365delA / p.N122IfsX8 
c.365delA / p.N122IfsX8 
c.488G>T / p.G163V 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
female 
male 
male 
34 
37 
68 
26 
22 
39 
65 
32 
32 
63 
29 
62 
20 
39 
56 
55 
68 
48 
23 
35 
40 
42 
16 
68 
25 
28 
51 
29 
23 
65 
72 
31 
25 
57 
35 
17 
51 
24 
22 
44 
36 
41 
65 
83 
68 
75 
63 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.581C>T / p.T194I 
c.704C>A / p.S235Y 
c.744_745delTA / p.F248LfsX7 
c.744_745delTA / p.F248LfsX7 
c.744_745delTA / p.F248LfsX7 
c.796G>T / p.D266Y 
c.796G>T / p.D266Y 
c.827G>A / p.S276N 
c.870G>C / p.M290I 
c.901C>T / p.R301X 
c.901C>T / p.R301X 
c.901C>T / p.R301X 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1033T>C / p.S345P 
c.1055_1057dupCTA / p.A352_M353insT 
c.1147_1149del / p.F383del 
c.1147_1149del / p.F383del 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9 
c.1167dupT / p.V390CfsX9  
c.1235_1236delCT / p.T412SfsX38 
c.640-3C>G / Cons. Splice Site 
c.370-2A>G / Cons. Splice Site 
Whole Exon 2 / Null-allele 
Not available* 
c.352C>T / p.R118C 
c.644A>G / p.N215S 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Classic 
Later-Onset 
Later-Onset 
  
male 
male 
male 
female 
female 
female 
female 
female 
male 
male 
male 
female 
female 
 
65 
44 
41 
33 
37 
53 
73 
48 
45 
23 
55 
53 
41 
 
c.902G>A / p.R301Q 
c.902G>A / p.R301Q 
c.1196G>C / p.W399S 
c.337T>C / p.F113L 
c.902G>A / p.R301Q 
c.902G>A / p.R301Q 
c.902G>A / p.R301Q 
c.902G>A / p.R301Q 
c.376A>G / p.S126G 
c.376A>G / p.S126G 
c.376A>G / p.S126G 
c.376A>G / p.S126G 
c.416A>G / p.N139S 
 
Later-Onset 
Later-Onset 
Later-Onset 
Later-Onset 
Later-Onset 
Later-Onset 
Later-Onset 
Later-Onset 
Benign 
Benign 
Benign 
Benign 
Benign 
 
* The original genetic report of this patient, who died in between, was not any more available. The Classic phenotype has 
been confirmed by clinical symptoms: cardiomyopathy, nephropathy, cornea verticillata, hypohydrosis. 
